Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Study Coverage
1.1 Introduction to Cell and Gene Therapy CDMO Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Cell and Gene Therapy CDMO Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Autologous Cell Therapy Products
1.2.3 Allogeneic Cell Therapy Products
1.3 Market Segmentation by Application
1.3.1 Global Cell and Gene Therapy CDMO Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cell and Gene Therapy CDMO Services Revenue Estimates and Forecasts 2020-2031
2.2 Global Cell and Gene Therapy CDMO Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Cell and Gene Therapy CDMO Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Cell and Gene Therapy CDMO Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Autologous Cell Therapy Products Market Size by Players
3.3.2 Allogeneic Cell Therapy Products Market Size by Players
3.4 Global Cell and Gene Therapy CDMO Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Cell and Gene Therapy CDMO Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Cell and Gene Therapy CDMO Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Cell and Gene Therapy CDMO Services Market Size by Type (2020-2031)
6.4 North America Cell and Gene Therapy CDMO Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Cell and Gene Therapy CDMO Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Cell and Gene Therapy CDMO Services Market Size by Type (2020-2031)
7.4 Europe Cell and Gene Therapy CDMO Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Cell and Gene Therapy CDMO Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Cell and Gene Therapy CDMO Services Market Size by Type (2020-2031)
8.4 Asia-Pacific Cell and Gene Therapy CDMO Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Cell and Gene Therapy CDMO Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Cell and Gene Therapy CDMO Services Market Size by Type (2020-2031)
9.4 Central and South America Cell and Gene Therapy CDMO Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Cell and Gene Therapy CDMO Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Cell and Gene Therapy CDMO Services Market Size by Type (2020-2031)
10.4 Middle East and Africa Cell and Gene Therapy CDMO Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Cell and Gene Therapy CDMO Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Catalent
11.1.1 Catalent Corporation Information
11.1.2 Catalent Business Overview
11.1.3 Catalent Cell and Gene Therapy CDMO Services Product Features and Attributes
11.1.4 Catalent Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.1.5 Catalent Cell and Gene Therapy CDMO Services Revenue by Product in 2024
11.1.6 Catalent Cell and Gene Therapy CDMO Services Revenue by Application in 2024
11.1.7 Catalent Cell and Gene Therapy CDMO Services Revenue by Geographic Area in 2024
11.1.8 Catalent Cell and Gene Therapy CDMO Services SWOT Analysis
11.1.9 Catalent Recent Developments
11.2 Lonza
11.2.1 Lonza Corporation Information
11.2.2 Lonza Business Overview
11.2.3 Lonza Cell and Gene Therapy CDMO Services Product Features and Attributes
11.2.4 Lonza Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.2.5 Lonza Cell and Gene Therapy CDMO Services Revenue by Product in 2024
11.2.6 Lonza Cell and Gene Therapy CDMO Services Revenue by Application in 2024
11.2.7 Lonza Cell and Gene Therapy CDMO Services Revenue by Geographic Area in 2024
11.2.8 Lonza Cell and Gene Therapy CDMO Services SWOT Analysis
11.2.9 Lonza Recent Developments
11.3 Thermo Fisher
11.3.1 Thermo Fisher Corporation Information
11.3.2 Thermo Fisher Business Overview
11.3.3 Thermo Fisher Cell and Gene Therapy CDMO Services Product Features and Attributes
11.3.4 Thermo Fisher Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.3.5 Thermo Fisher Cell and Gene Therapy CDMO Services Revenue by Product in 2024
11.3.6 Thermo Fisher Cell and Gene Therapy CDMO Services Revenue by Application in 2024
11.3.7 Thermo Fisher Cell and Gene Therapy CDMO Services Revenue by Geographic Area in 2024
11.3.8 Thermo Fisher Cell and Gene Therapy CDMO Services SWOT Analysis
11.3.9 Thermo Fisher Recent Developments
11.4 WuXi AppTec
11.4.1 WuXi AppTec Corporation Information
11.4.2 WuXi AppTec Business Overview
11.4.3 WuXi AppTec Cell and Gene Therapy CDMO Services Product Features and Attributes
11.4.4 WuXi AppTec Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.4.5 WuXi AppTec Cell and Gene Therapy CDMO Services Revenue by Product in 2024
11.4.6 WuXi AppTec Cell and Gene Therapy CDMO Services Revenue by Application in 2024
11.4.7 WuXi AppTec Cell and Gene Therapy CDMO Services Revenue by Geographic Area in 2024
11.4.8 WuXi AppTec Cell and Gene Therapy CDMO Services SWOT Analysis
11.4.9 WuXi AppTec Recent Developments
11.5 Charles River
11.5.1 Charles River Corporation Information
11.5.2 Charles River Business Overview
11.5.3 Charles River Cell and Gene Therapy CDMO Services Product Features and Attributes
11.5.4 Charles River Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.5.5 Charles River Cell and Gene Therapy CDMO Services Revenue by Product in 2024
11.5.6 Charles River Cell and Gene Therapy CDMO Services Revenue by Application in 2024
11.5.7 Charles River Cell and Gene Therapy CDMO Services Revenue by Geographic Area in 2024
11.5.8 Charles River Cell and Gene Therapy CDMO Services SWOT Analysis
11.5.9 Charles River Recent Developments
11.6 OxfordBioMedica
11.6.1 OxfordBioMedica Corporation Information
11.6.2 OxfordBioMedica Business Overview
11.6.3 OxfordBioMedica Cell and Gene Therapy CDMO Services Product Features and Attributes
11.6.4 OxfordBioMedica Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.6.5 OxfordBioMedica Recent Developments
11.7 BrammerBio
11.7.1 BrammerBio Corporation Information
11.7.2 BrammerBio Business Overview
11.7.3 BrammerBio Cell and Gene Therapy CDMO Services Product Features and Attributes
11.7.4 BrammerBio Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.7.5 BrammerBio Recent Developments
11.8 CELLfor CURE
11.8.1 CELLfor CURE Corporation Information
11.8.2 CELLfor CURE Business Overview
11.8.3 CELLfor CURE Cell and Gene Therapy CDMO Services Product Features and Attributes
11.8.4 CELLfor CURE Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.8.5 CELLfor CURE Recent Developments
11.9 OBiO Technology
11.9.1 OBiO Technology Corporation Information
11.9.2 OBiO Technology Business Overview
11.9.3 OBiO Technology Cell and Gene Therapy CDMO Services Product Features and Attributes
11.9.4 OBiO Technology Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.9.5 OBiO Technology Recent Developments
11.10 GenScript
11.10.1 GenScript Corporation Information
11.10.2 GenScript Business Overview
11.10.3 GenScript Cell and Gene Therapy CDMO Services Product Features and Attributes
11.10.4 GenScript Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Esco
11.11.1 Esco Corporation Information
11.11.2 Esco Business Overview
11.11.3 Esco Cell and Gene Therapy CDMO Services Product Features and Attributes
11.11.4 Esco Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.11.5 Esco Recent Developments
11.12 Nikon
11.12.1 Nikon Corporation Information
11.12.2 Nikon Business Overview
11.12.3 Nikon Cell and Gene Therapy CDMO Services Product Features and Attributes
11.12.4 Nikon Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.12.5 Nikon Recent Developments
11.13 FUJIFILM
11.13.1 FUJIFILM Corporation Information
11.13.2 FUJIFILM Business Overview
11.13.3 FUJIFILM Cell and Gene Therapy CDMO Services Product Features and Attributes
11.13.4 FUJIFILM Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.13.5 FUJIFILM Recent Developments
11.14 Pharmaron
11.14.1 Pharmaron Corporation Information
11.14.2 Pharmaron Business Overview
11.14.3 Pharmaron Cell and Gene Therapy CDMO Services Product Features and Attributes
11.14.4 Pharmaron Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.14.5 Pharmaron Recent Developments
11.15 Porton
11.15.1 Porton Corporation Information
11.15.2 Porton Business Overview
11.15.3 Porton Cell and Gene Therapy CDMO Services Product Features and Attributes
11.15.4 Porton Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.15.5 Porton Recent Developments
11.16 Medicilon
11.16.1 Medicilon Corporation Information
11.16.2 Medicilon Business Overview
11.16.3 Medicilon Cell and Gene Therapy CDMO Services Product Features and Attributes
11.16.4 Medicilon Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.16.5 Medicilon Recent Developments
11.17 JOINN Laboratories
11.17.1 JOINN Laboratories Corporation Information
11.17.2 JOINN Laboratories Business Overview
11.17.3 JOINN Laboratories Cell and Gene Therapy CDMO Services Product Features and Attributes
11.17.4 JOINN Laboratories Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.17.5 JOINN Laboratories Recent Developments
11.18 Sofpromed
11.18.1 Sofpromed Corporation Information
11.18.2 Sofpromed Business Overview
11.18.3 Sofpromed Cell and Gene Therapy CDMO Services Product Features and Attributes
11.18.4 Sofpromed Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.18.5 Sofpromed Recent Developments
11.19 eXmoor
11.19.1 eXmoor Corporation Information
11.19.2 eXmoor Business Overview
11.19.3 eXmoor Cell and Gene Therapy CDMO Services Product Features and Attributes
11.19.4 eXmoor Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.19.5 eXmoor Recent Developments
11.20 OmniaBio
11.20.1 OmniaBio Corporation Information
11.20.2 OmniaBio Business Overview
11.20.3 OmniaBio Cell and Gene Therapy CDMO Services Product Features and Attributes
11.20.4 OmniaBio Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.20.5 OmniaBio Recent Developments
11.21 RoslinCT
11.21.1 RoslinCT Corporation Information
11.21.2 RoslinCT Business Overview
11.21.3 RoslinCT Cell and Gene Therapy CDMO Services Product Features and Attributes
11.21.4 RoslinCT Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.21.5 RoslinCT Recent Developments
11.22 BioCentriq
11.22.1 BioCentriq Corporation Information
11.22.2 BioCentriq Business Overview
11.22.3 BioCentriq Cell and Gene Therapy CDMO Services Product Features and Attributes
11.22.4 BioCentriq Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.22.5 BioCentriq Recent Developments
11.23 PolTREG
11.23.1 PolTREG Corporation Information
11.23.2 PolTREG Business Overview
11.23.3 PolTREG Cell and Gene Therapy CDMO Services Product Features and Attributes
11.23.4 PolTREG Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.23.5 PolTREG Recent Developments
11.24 Miltenyi Bioindustry
11.24.1 Miltenyi Bioindustry Corporation Information
11.24.2 Miltenyi Bioindustry Business Overview
11.24.3 Miltenyi Bioindustry Cell and Gene Therapy CDMO Services Product Features and Attributes
11.24.4 Miltenyi Bioindustry Cell and Gene Therapy CDMO Services Revenue and Gross Margin (2020-2025)
11.24.5 Miltenyi Bioindustry Recent Developments
12 Cell and Gene Therapy CDMO ServicesIndustry Chain Analysis
12.1 Cell and Gene Therapy CDMO Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Cell and Gene Therapy CDMO Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Cell and Gene Therapy CDMO Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Cell and Gene Therapy CDMO Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Cell and Gene Therapy CDMO Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Cell and Gene Therapy CDMO Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Cell and Gene Therapy CDMO Services Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Cell and Gene Therapy CDMO Services Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Cell and Gene Therapy CDMO Services Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Cell and Gene Therapy CDMO Services Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Cell and Gene Therapy CDMO Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Gene Therapy CDMO Services as of 2024)
Table 11. Global Cell and Gene Therapy CDMO Services Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Cell and Gene Therapy CDMO Services Companies Headquarters
Table 13. Global Cell and Gene Therapy CDMO Services Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Cell and Gene Therapy CDMO Services Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Cell and Gene Therapy CDMO Services Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Cell and Gene Therapy CDMO Services Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Cell and Gene Therapy CDMO Services Revenue by Application (2026-2031) & (US$ Million)
Table 21. Cell and Gene Therapy CDMO Services High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Cell and Gene Therapy CDMO Services Growth Accelerators and Market Barriers
Table 25. North America Cell and Gene Therapy CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Cell and Gene Therapy CDMO Services Growth Accelerators and Market Barriers
Table 27. Europe Cell and Gene Therapy CDMO Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Cell and Gene Therapy CDMO Services Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Cell and Gene Therapy CDMO Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Cell and Gene Therapy CDMO Services Investment Opportunities and Key Challenges
Table 31. Central and South America Cell and Gene Therapy CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Cell and Gene Therapy CDMO Services Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Cell and Gene Therapy CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Catalent Corporation Information
Table 35. Catalent Description and Major Businesses
Table 36. Catalent Product Features and Attributes
Table 37. Catalent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Catalent Revenue Proportion by Product in 2024
Table 39. Catalent Revenue Proportion by Application in 2024
Table 40. Catalent Revenue Proportion by Geographic Area in 2024
Table 41. Catalent Cell and Gene Therapy CDMO Services SWOT Analysis
Table 42. Catalent Recent Developments
Table 43. Lonza Corporation Information
Table 44. Lonza Description and Major Businesses
Table 45. Lonza Product Features and Attributes
Table 46. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Lonza Revenue Proportion by Product in 2024
Table 48. Lonza Revenue Proportion by Application in 2024
Table 49. Lonza Revenue Proportion by Geographic Area in 2024
Table 50. Lonza Cell and Gene Therapy CDMO Services SWOT Analysis
Table 51. Lonza Recent Developments
Table 52. Thermo Fisher Corporation Information
Table 53. Thermo Fisher Description and Major Businesses
Table 54. Thermo Fisher Product Features and Attributes
Table 55. Thermo Fisher Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Thermo Fisher Revenue Proportion by Product in 2024
Table 57. Thermo Fisher Revenue Proportion by Application in 2024
Table 58. Thermo Fisher Revenue Proportion by Geographic Area in 2024
Table 59. Thermo Fisher Cell and Gene Therapy CDMO Services SWOT Analysis
Table 60. Thermo Fisher Recent Developments
Table 61. WuXi AppTec Corporation Information
Table 62. WuXi AppTec Description and Major Businesses
Table 63. WuXi AppTec Product Features and Attributes
Table 64. WuXi AppTec Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. WuXi AppTec Revenue Proportion by Product in 2024
Table 66. WuXi AppTec Revenue Proportion by Application in 2024
Table 67. WuXi AppTec Revenue Proportion by Geographic Area in 2024
Table 68. WuXi AppTec Cell and Gene Therapy CDMO Services SWOT Analysis
Table 69. WuXi AppTec Recent Developments
Table 70. Charles River Corporation Information
Table 71. Charles River Description and Major Businesses
Table 72. Charles River Product Features and Attributes
Table 73. Charles River Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Charles River Revenue Proportion by Product in 2024
Table 75. Charles River Revenue Proportion by Application in 2024
Table 76. Charles River Revenue Proportion by Geographic Area in 2024
Table 77. Charles River Cell and Gene Therapy CDMO Services SWOT Analysis
Table 78. Charles River Recent Developments
Table 79. OxfordBioMedica Corporation Information
Table 80. OxfordBioMedica Description and Major Businesses
Table 81. OxfordBioMedica Product Features and Attributes
Table 82. OxfordBioMedica Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. OxfordBioMedica Recent Developments
Table 84. BrammerBio Corporation Information
Table 85. BrammerBio Description and Major Businesses
Table 86. BrammerBio Product Features and Attributes
Table 87. BrammerBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. BrammerBio Recent Developments
Table 89. CELLfor CURE Corporation Information
Table 90. CELLfor CURE Description and Major Businesses
Table 91. CELLfor CURE Product Features and Attributes
Table 92. CELLfor CURE Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. CELLfor CURE Recent Developments
Table 94. OBiO Technology Corporation Information
Table 95. OBiO Technology Description and Major Businesses
Table 96. OBiO Technology Product Features and Attributes
Table 97. OBiO Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. OBiO Technology Recent Developments
Table 99. GenScript Corporation Information
Table 100. GenScript Description and Major Businesses
Table 101. GenScript Product Features and Attributes
Table 102. GenScript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. GenScript Recent Developments
Table 104. Esco Corporation Information
Table 105. Esco Description and Major Businesses
Table 106. Esco Product Features and Attributes
Table 107. Esco Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Esco Recent Developments
Table 109. Nikon Corporation Information
Table 110. Nikon Description and Major Businesses
Table 111. Nikon Product Features and Attributes
Table 112. Nikon Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Nikon Recent Developments
Table 114. FUJIFILM Corporation Information
Table 115. FUJIFILM Description and Major Businesses
Table 116. FUJIFILM Product Features and Attributes
Table 117. FUJIFILM Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. FUJIFILM Recent Developments
Table 119. Pharmaron Corporation Information
Table 120. Pharmaron Description and Major Businesses
Table 121. Pharmaron Product Features and Attributes
Table 122. Pharmaron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Pharmaron Recent Developments
Table 124. Porton Corporation Information
Table 125. Porton Description and Major Businesses
Table 126. Porton Product Features and Attributes
Table 127. Porton Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Porton Recent Developments
Table 129. Medicilon Corporation Information
Table 130. Medicilon Description and Major Businesses
Table 131. Medicilon Product Features and Attributes
Table 132. Medicilon Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Medicilon Recent Developments
Table 134. JOINN Laboratories Corporation Information
Table 135. JOINN Laboratories Description and Major Businesses
Table 136. JOINN Laboratories Product Features and Attributes
Table 137. JOINN Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. JOINN Laboratories Recent Developments
Table 139. Sofpromed Corporation Information
Table 140. Sofpromed Description and Major Businesses
Table 141. Sofpromed Product Features and Attributes
Table 142. Sofpromed Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Sofpromed Recent Developments
Table 144. eXmoor Corporation Information
Table 145. eXmoor Description and Major Businesses
Table 146. eXmoor Product Features and Attributes
Table 147. eXmoor Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. eXmoor Recent Developments
Table 149. OmniaBio Corporation Information
Table 150. OmniaBio Description and Major Businesses
Table 151. OmniaBio Product Features and Attributes
Table 152. OmniaBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. OmniaBio Recent Developments
Table 154. RoslinCT Corporation Information
Table 155. RoslinCT Description and Major Businesses
Table 156. RoslinCT Product Features and Attributes
Table 157. RoslinCT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. RoslinCT Recent Developments
Table 159. BioCentriq Corporation Information
Table 160. BioCentriq Description and Major Businesses
Table 161. BioCentriq Product Features and Attributes
Table 162. BioCentriq Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. BioCentriq Recent Developments
Table 164. PolTREG Corporation Information
Table 165. PolTREG Description and Major Businesses
Table 166. PolTREG Product Features and Attributes
Table 167. PolTREG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. PolTREG Recent Developments
Table 169. Miltenyi Bioindustry Corporation Information
Table 170. Miltenyi Bioindustry Description and Major Businesses
Table 171. Miltenyi Bioindustry Product Features and Attributes
Table 172. Miltenyi Bioindustry Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. Miltenyi Bioindustry Recent Developments
Table 174. Raw Materials Key Suppliers
Table 175. Distributors List
Table 176. Market Trends and Market Evolution
Table 177. Market Drivers and Opportunities
Table 178. Market Challenges, Risks, and Restraints
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources


List of Figures
Figure 1. Cell and Gene Therapy CDMO Services Product Picture
Figure 2. Global Cell and Gene Therapy CDMO Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Autologous Cell Therapy Products Product Picture
Figure 4. Allogeneic Cell Therapy Products Product Picture
Figure 5. Global Cell and Gene Therapy CDMO Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. SMBs
Figure 7. Large Companies
Figure 8. Cell and Gene Therapy CDMO Services Report Years Considered
Figure 9. Global Cell and Gene Therapy CDMO Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 11. Global Cell and Gene Therapy CDMO Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Cell and Gene Therapy CDMO Services Revenue Market Share by Region (2020-2031)
Figure 13. Global Cell and Gene Therapy CDMO Services Revenue Market Share Ranking (2024)
Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 15. Autologous Cell Therapy Products Revenue Market Share by Player in 2024
Figure 16. Allogeneic Cell Therapy Products Revenue Market Share by Player in 2024
Figure 17. Global Cell and Gene Therapy CDMO Services Revenue Market Share by Type (2020-2031)
Figure 18. Global Cell and Gene Therapy CDMO Services Revenue Market Share by Application (2020-2031)
Figure 19. North America Cell and Gene Therapy CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 20. North America Top 5 Players Cell and Gene Therapy CDMO Services Revenue (US$ Million) in 2024
Figure 21. North America Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Type (2020 - 2031)
Figure 22. North America Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 23. US Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 24. Canada Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 25. Mexico Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 26. Europe Cell and Gene Therapy CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 27. Europe Top 5 Players Cell and Gene Therapy CDMO Services Revenue (US$ Million) in 2024
Figure 28. Europe Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 29. Europe Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 30. Germany Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 31. France Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 32. U.K. Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 33. Italy Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 34. Russia Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Cell and Gene Therapy CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Top 8 Players Cell and Gene Therapy CDMO Services Revenue (US$ Million) in 2024
Figure 37. Asia-Pacific Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 38. Asia-Pacific Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 39. Indonesia Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 40. Japan Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 41. South Korea Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 42. Australia Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 43. India Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 44. Indonesia Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 45. Vietnam Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 46. Malaysia Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 47. Philippines Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 48. Singapore Cell and Gene Therapy CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 49. Central and South America Cell and Gene Therapy CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Central and South America Top 5 Players Cell and Gene Therapy CDMO Services Revenue (US$ Million) in 2024
Figure 51. Central and South America Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 52. Central and South America Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 53. Brazil Cell and Gene Therapy CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 54. Argentina Cell and Gene Therapy CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 55. Middle East and Africa Cell and Gene Therapy CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Middle East and Africa Top 5 Players Cell and Gene Therapy CDMO Services Revenue (US$ Million) in 2024
Figure 57. South America Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 58. Middle East and Africa Cell and Gene Therapy CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 59. GCC Countries Cell and Gene Therapy CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 60. Israel Cell and Gene Therapy CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 61. Egypt Cell and Gene Therapy CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 62. South Africa Cell and Gene Therapy CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 63. Cell and Gene Therapy CDMO Services Industry Chain Mapping
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed